• Home
  • Adverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors
  • Author : Giuseppe Tridente
  • Publsiher : Academic Press
  • Release : 08 May 2017
  • ISBN : 0128094451
  • Pages : 736 pages
  • Rating : 4/5 from 21 ratings
GET THIS BOOKAdverse Events and Oncotargeted Kinase Inhibitors

Summary:
Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug class that has recently been introduced for human therapy. This book compiles a comprehensive safety profile of each TKI from experiences in official therapeutic indications, also exploring off-label exploratory investigations and postmarketing pharmaceutical surveillance databases. A brief history of each drug’s development and submission is provided, along with a more detailed analysis of the mechanism(s) of action involved in therapeutic activity or related to the insurgence of specific adverse events. Early chapters focus on general characteristics of TKIs, typology, and classification of adverse events, while the final chapters analyze TKIs as AE inducers and classes of AEs by system or organ involvement. This comprehensive resource compiles and critically reviews all of the relevant safety data for this class of drugs, with the goal of improving the understanding of pathogenesis and facilitating the prevention, monitoring, and management of these adverse events. Offers a unique and comprehensive publication on the adverse events associated with a new and fast-growing class of medicines Provides a systematic analysis of adverse events aimed at better prevention through understanding and offering insights for the development of safer drugs Uses practical guidelines to establish a leading reference on this class of drugs for educators, researchers, drug developers, clinicians, safety professionals, and more


Adverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors
  • Author : Giuseppe Tridente
  • Publisher : Academic Press
  • Release : 08 May 2017
GET THIS BOOKAdverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug class that has recently been introduced for human therapy. This book compiles a comprehensive safety profile of each TKI from experiences in official therapeutic indications, also exploring off-label exploratory investigations and postmarketing pharmaceutical surveillance databases. A brief history of each drug’s development and submission is provided, along with a more detailed analysis of the mechanism(s)




Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
  • Author : Anonim
  • Publisher : Academic Press
  • Release : 21 November 2018
GET THIS BOOKProtein Kinase Inhibitors as Sensitizing Agents for Chemotherapy

Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic,



Anti-fibrotic Drug Discovery

Anti-fibrotic Drug Discovery
  • Author : Jehrod Brenneman,Malliga R Iyer
  • Publisher : Royal Society of Chemistry
  • Release : 17 February 2020
GET THIS BOOKAnti-fibrotic Drug Discovery

Fibrosis is a condition with globally high unmet medical need, and as such is a highly active area of academic and pharmaceutical research covering multiple treatment targets, organs, tissues and therapeutic approaches. Anti-fibrotic Drug Discovery is a single source reference for the latest drug-discovery approaches to tackle fibrosis in various tissues, comprehensively covering recent success and future perspectives on emerging therapeutic intervention points. The book highlights significant pre-clinical and clinical drugs currently being developed globally for this disorder. This book


Hepatocellular Carcinoma

Hepatocellular Carcinoma
  • Author : Yujin Hoshida
  • Publisher : Springer
  • Release : 05 August 2019
GET THIS BOOKHepatocellular Carcinoma

This book provides a comprehensive overview of the current limitations and unmet needs in Hepatocellular Carcinoma (HCC) diagnosis, treatment, and prevention. It also provides newly emerging concepts, approaches, and technologies to address challenges. Topics covered include changing landscape of HCC etiologies in association with health disparities, framework of clinical management algorithm, new and experimental modalities of HCC diagnosis and prognostication, multidisciplinary treatment options including rapidly evolving molecular targeted therapies and immune therapies, multi-omics molecular characterization, and clinically relevant experimental models.


Cancer Drug Design and Discovery

Cancer Drug Design and Discovery
  • Author : Stephen Neidle
  • Publisher : Elsevier
  • Release : 28 April 2011
GET THIS BOOKCancer Drug Design and Discovery

The ultimate source of information on the design of new anticancer agents, emphasizing small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumors. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing


Osteoimmunology

Osteoimmunology
  • Author : Joseph Lorenzo,Mark Horowitz,Yongwon Choi,Hiroshi Takayanagi
  • Publisher : Academic Press
  • Release : 24 September 2010
GET THIS BOOKOsteoimmunology

Bone and the immune system are both complex tissues, which, respectively, regulate the skeleton and the body's responses to invading pathogens. Critical interactions between these two organ systems frequently occur, particularly in the development of immune cells in the bone marrow and for the function of bone cells in health and disease. This book provides a detailed overview of the many ways that bone and immune cells interact. The goal is to provide basic and clinical scientists with a better


Cardio-Oncology

Cardio-Oncology
  • Author : Roberta A. Gottlieb,Puja K Mehta
  • Publisher : Academic Press
  • Release : 26 November 2016
GET THIS BOOKCardio-Oncology

Cardio-Oncology: Principles, Prevention and Management is a clinical volume that focuses on the basic science of cardio-oncology, addresses cardiotoxicity as a consequence of cancer therapy, and discusses prevention, diagnosis and management of cardiovascular disease in patients with cancer. This comprehensive volume presents unique perspectives ranging from basic science to clinical medicine in the field of cardio-oncology. It would be a valuable resource for cardiologists, oncologists, internists, and pediatricians caring for patients with cancer who have cardiovascular risk factors, as well


Williams Hematology, 10th Edition

Williams Hematology, 10th Edition
  • Author : Kenneth Kaushansky,Marshall A. Lichtman,Josef T. Prchal,Marcel M. Levi,Linda J. Burns
  • Publisher : McGraw Hill Professional
  • Release : 14 January 2021
GET THIS BOOKWilliams Hematology, 10th Edition

The landmark text that has guided generations of hematologists and related practitioners―updated with the latest research findings and improved format and presentation Long revered for its comprehensiveness and extraordinary depth of detail, Williams Hematology provides essential coverage of the origins, pathophysiological mechanisms, and management of benign and malignant disorders of blood and marrow cells and coagulation proteins. The text contains a wealth of basic science and translational pathophysiology for optimal, lifelong learning. Experts in research and clinical hematology, the


Clinical Gynecologic Oncology E-Book

Clinical Gynecologic Oncology E-Book
  • Author : Philip J. DiSaia,William T. Creasman,Robert S Mannel,D. Scott McMeekin,David G Mutch
  • Publisher : Elsevier Health Sciences
  • Release : 04 February 2017
GET THIS BOOKClinical Gynecologic Oncology E-Book

The most readable, most comprehensive book in its field, Clinical Gynecologic Oncology, 9th Edition is the leading reference for diagnosis and treatment of gynecologic cancers – a must-have reference for improving outcomes and providing effective care. A "who’s who" list of contributing authors, under the editorial direction of Drs. Philip DiSaia and William Creasman, provides expert guidance on clinical presentations and management, now fully up to date with a brand-new design for faster, easier reference. Contains useful appendices covering staging,


Renal Disease in Cancer Patients

Renal Disease in Cancer Patients
  • Author : Kevin W. Finkel,Scott C. Howard
  • Publisher : Academic Press
  • Release : 02 September 2013
GET THIS BOOKRenal Disease in Cancer Patients

Renal Disease in Cancer Patients is a translational reference detailing the nephrological problems unique to patients with cancer in an organized and authoritative fashion. This book provides a common language for nephrologists, oncologists, hematologists, and other clinicians who treat cancer patients, to discuss the development of renal diseases in the context of cancer and options for their optimum diagnosis, management, and treatment. With the advent of better supportive care and the era of personalized medicine, patients with cancer are living


Chemical Proteomics

Chemical Proteomics
  • Author : Gerard Drewes,Marcus Bantscheff
  • Publisher : Humana Press
  • Release : 17 November 2011
GET THIS BOOKChemical Proteomics

The multidisciplinary science of chemical proteomics studies how small molecules of synthetic or natural origin bind to proteins and modulate their function. In Chemical Proteomics: Methods and Protocols, expert researchers in the field provide key techniques to investigate chemical proteomics focusing on analytical strategies, how probes are generated, techniques for the discovery of small molecule targets and the probing of target function, and small molecule ligand and drug discovery. Written in the highly successful Methods in Molecular BiologyTM series format,


Adverse Events with Biomedicines

Adverse Events with Biomedicines
  • Author : Giuseppe Tridente
  • Publisher : Springer Science & Business Media
  • Release : 09 December 2013
GET THIS BOOKAdverse Events with Biomedicines

This monograph gathers and evaluates data on adverse events (AEs) associated specifically with those “biomedicines” – monoclonal antibodies, fusion proteins, and cytokines – that have recently entered therapeutic use in humans. All AEs observed when using each member of this new drug class are covered, with a view to improving understanding of pathogenesis, facilitating prevention, monitoring, and control, and contributing to the development of better drugs that provide benefits while minimizing risk. Further aspects here examined include the role of drug mechanisms